Division of Cardiology, University of Perugia School of Medicine, Perugia, Italy.
Eur Heart J. 2010 Feb;31(4):430-8. doi: 10.1093/eurheartj/ehp457. Epub 2009 Nov 10.
Brief episode(s) of ischaemia may increase cardiac tolerance to a subsequent major ischaemic insult ('preconditioning'). Nitrates can pharmacologically mimic ischaemic preconditioning in animals. In this study, we investigated whether antecedent nitrate therapy affords protection toward acute ischaemic events using data from the Global Registry of Acute Coronary Events.
The dataset comprised 52,693 patients from 123 centres in 14 countries: 42,138 (80%) were nitrate-naïve and 10,555 (20%) were on chronic nitrates at admission. In nitrate-naïve patients, admission diagnosis was ST-segment elevation myocardial infarction (STEMI) in 41%, whereas 59% presented with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). In contrast, only 18% nitrate users showed STEMI, whereas 82% presented with NSTE-ACS. Thus, among nitrate users clinical presentation was tilted toward NSTE-ACS by more than four-fold, STEMI occurring in less than one of five patients (P < 0.0001). After adjustment (age, sex, medical history, prior therapy, revascularization, previous angina), chronic nitrate use remained independent predictor of NSTE-ACS (OR 1.36; 95% CI 1.26-1.46; P < 0.0001). Furthermore, regardless of presentation, within both STEMI and NSTEMI populations, antecedent nitrate use was associated with significantly lower levels of CK-MB and troponin (P < 0.0001 for all).
In this large multinational registry, chronic nitrate use was associated with a shift away from STEMI in favour of NSTE-ACS and with less release of markers of cardiac necrosis. These findings suggest that in nitrate users acute coronary events may develop to a smaller extent. Randomized, placebo-controlled trials are warranted to establish whether nitrate therapy may pharmacologically precondition the heart toward ischaemic episodes.
短暂的缺血发作可能会增加心脏对随后的重大缺血损伤的耐受能力(“预处理”)。硝酸酯类药物可以在动物中模拟缺血预处理。在这项研究中,我们使用来自全球急性冠状动脉事件注册研究的数据,研究了先前的硝酸酯治疗是否能为急性缺血事件提供保护。
该数据集包括来自 14 个国家 123 个中心的 52693 名患者:42138 名(80%)为硝酸酯类药物初治患者,10555 名(20%)入院时正在服用慢性硝酸酯类药物。在硝酸酯类药物初治患者中,入院诊断为 ST 段抬高型心肌梗死(STEMI)占 41%,而非 ST 段抬高型急性冠状动脉综合征(NSTE-ACS)占 59%。相比之下,只有 18%的硝酸酯类药物使用者出现 STEMI,而 82%的患者出现 NSTE-ACS。因此,在硝酸酯类药物使用者中,临床表现更倾向于 NSTE-ACS,四倍以上的患者出现 STEMI(P<0.0001)。经过调整(年龄、性别、病史、既往治疗、血运重建、既往心绞痛),慢性硝酸酯类药物的使用仍然是 NSTE-ACS 的独立预测因素(OR 1.36;95%CI 1.26-1.46;P<0.0001)。此外,无论表现如何,在 STEMI 和 NSTEMI 患者中,先前使用硝酸酯类药物与 CK-MB 和肌钙蛋白水平显著降低相关(所有 P<0.0001)。
在这项大型跨国注册研究中,慢性硝酸酯类药物的使用与 STEMI 向 NSTE-ACS 的转变有关,并且与心脏坏死标志物的释放减少有关。这些发现表明,在硝酸酯类药物使用者中,急性冠状动脉事件的发生程度可能较小。需要进行随机、安慰剂对照试验来确定硝酸酯类药物治疗是否可以使心脏对缺血发作产生药理学预处理。